---
title: Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients
nct_id: NCT00570011
overall_status: COMPLETED
phase: PHASE3
sponsor: Eli Lilly and Company
study_type: INTERVENTIONAL
primary_condition: Growth Hormone Deficiency
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00570011.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00570011"
ct_last_update_post_date: 2007-12-11
last_seen_at: "2026-05-12T06:33:55.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Low and Conventional Dose of Somatropin in Growth Hormone Deficient Adult Patients

**Official Title:** Efficacy of Two Different Dose Regimens of Somatropin in Growth Hormone Deficient Adult Patients

**NCT ID:** [NCT00570011](https://clinicaltrials.gov/study/NCT00570011)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE3
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 112
- **Lead Sponsor:** Eli Lilly and Company
- **Collaborators:** University of Naples, University of Padova, University of Milan, University of Pisa
- **Conditions:** Growth Hormone Deficiency
- **Start Date:** 1997-06
- **Completion Date:** 1998-12
- **CT.gov Last Update:** 2007-12-11

## Brief Summary

An international study in which patients with GHD were randomized to receive somatropin at a dose of either 3 microg/kg/day or 6 microg/kg/day for the first three months. The dose was then doubled (6 microg/kg/day, LD or 12 microg/kg/day, CD) for the next three-months.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

Patients may be included in the study only if they meet all of the following criteria:

1. Adult males and females with GHD, arising during adult life from pituitary ablation or failure, onset of GHD have taken place at least 1 year before entering the study, or,
2. Adult males and females with GHD either idiopathic or secondary to pituitary disease arising in childhood.
3. Demonstrated GHD as documented by a negative response to a standard GH stimulation test within the last 5 years previous year (see Section 3.4.3, part b). Maximal peak must be less than 3.0 ng/ml.
4. Receiving replacement for other deficient hormones for at least 3 months prior to the start of the study, where necessary.
5. Have given informed consent.

Exclusion Criteria:

Patients will be excluded from the study for any of the following reasons:

1. Patients with clinically significant pulmonary, cardiac, hepatic, renal or neuromuscular disease or with chromosomal or genetic malformation syndromes.
2. Patients who have any evidence of an active tumorous process. Intercranial lesions must be inactive and any antitumour therapy must be complete.
3. Pregnant women and lactating females or women who decide to become pregnant during the study and who are not taking adequate contraceptives.
4. Patients thought unlikely to comply with the protocol.
5. Patients taking an investigational drug in the previous month.
```

## Arms

- **1** (EXPERIMENTAL)
- **2** (EXPERIMENTAL)

## Interventions

- **Somatropin** (DRUG) — 3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
- **Somatropin** (DRUG) — 6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.

## Primary Outcomes

- **Plasminogen activator inhibitor-1 (PAI-1) and tissue plasminogen activator (t-PA) as a function of changes in insulin levels was investigated.** _(time frame: 6 months)_

## Secondary Outcomes

- **Serum concentrations of Leptin, Insulin, IGFBP1, IGFBP2, IGF2** _(time frame: 6 months)_

## Locations (1)

- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.for additional information regarding investigative sites for this trial, contact 1-877-ctlilly (1-877-285-4559, 1-317-615-4559) mon - fri from 9 am to 5 pm eastern time (utc/gmt - 5 hours, est), or speak with your personal physician.|indianapolis|indiana|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00570011.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00570011*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*